African-American kids with certain PCSK9 gene changes (Y142X or C679X) have lower 'bad' cholesterol from a young age—this finding is from the abstract summary - full study details were not available
Evidence from Studies
Supporting (1)
Community contributions welcome
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether pharmacologic PCSK9 inhibition mimics the lipid-lowering effect seen in natural mutation carriers.
A double-blind RCT of 400 African-American children aged 6–12 years, randomized to receive either PCSK9 inhibitor (alirocumab 75 mg every 2 weeks) or placebo for 6 months, measuring change in LDL cholesterol as primary outcome, with subgroup analysis by Y142X/C679X carrier status.
The aggregate evidence across studies on the magnitude of LDL reduction associated with PCSK9 nonsense mutations in African-American populations.
A systematic review of all cohort and cross-sectional studies reporting LDL cholesterol in African-American children and adults with Y142X or C679X mutations, pooling effect sizes using random-effects models, assessing publication bias and study quality.
The longitudinal relationship between PCSK9 nonsense mutations and LDL cholesterol from childhood through adulthood in African-Americans.
A prospective cohort study following 1,500 African-American children from age 4 to 40 years, genotyped for Y142X and C679X, with biannual lipid panels and adjustment for socioeconomic, dietary, and clinical confounders.